- Report
- April 2025
- 93 Pages
Global
From €5232EUR$5,600USD£4,426GBP
- Report
- March 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- March 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- May 2024
- 137 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Report
- September 2024
- 343 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- July 2024
- 150 Pages
Global
From €3503EUR$3,750USD£2,964GBP
- Report
- December 2024
- 30 Pages
Global
From €2569EUR$2,750USD£2,173GBP
- Report
- May 2021
- 50 Pages
China
From €2429EUR$2,600USD£2,055GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
€1401EUR$1,500USD£1,185GBP
- Report
- March 2023
- 147 Pages
Global
From €4623EUR$4,949USD£3,911GBP
- Report
- November 2023
- 135 Pages
Global
From €3737EUR$4,000USD£3,161GBP
- Report
- April 2023
- 117 Pages
Global
From €4438EUR$4,750USD£3,754GBP
- Report
- January 2023
- 85 Pages
Europe
From €1401EUR$1,500USD£1,185GBP
- Report
- January 2024
- 156 Pages
United States
€3550EUR$3,800USD£3,003GBP
- Report
- January 2024
- 114 Pages
United States
€3270EUR$3,500USD£2,766GBP
- Report
- July 2018
- 33 Pages
Global
From €9342EUR$10,000USD£7,903GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €467EUR$500USD£395GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- December 2022
- 210 Pages
Global
From €3447EUR$3,690USD£2,916GBP

Tiotropium is a long-acting anticholinergic drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both an inhaler and a dry powder inhaler. Tiotropium is the only long-acting anticholinergic approved for the treatment of COPD. It is also used to treat asthma and other respiratory conditions.
Tiotropium is a popular drug in the respiratory drugs market, as it is effective in treating COPD and other respiratory conditions. It is also well-tolerated, with few side effects. It is available in both generic and brand-name forms, making it accessible to a wide range of patients.
Some companies in the Tiotropium market include Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Show Less Read more